according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Moxifloxacin Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 199 Wenhai North Road

HEDA, Hangzhou - Zhejiang Province - CHINA 310018

Telephone : 908-740-4000

Emergency telephone number: 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance: liquidColour: yellowOdour: odourless

Not a hazardous substance or mixture.

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Physical and chemical hazards

Not classified based on available information.

Health hazards

Not classified based on available information.

Environmental hazards

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	
Moxifloxacin HCL	186826-86-8	>= 0.1 -<= 0.2	

4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air,

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

In case of eye contact Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

None known.

Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

Hazardous combustion prod: :

ucts

No hazardous combustion products are known

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only Advice on safe handling : Avoid inh

Use only with adequate ventilation. Avoid inhalation of vapour or mist.

Do not swallow.

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Moxifloxacin HCL	186826-86-8	TWA	1000 μg/m3 (OEB	Internal
			1)	

Engineering measures: Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hand protection

: Work uniform or laboratory coat.

Material : Chemical-resistant gloves

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Colour : yellow

Odour : odourless

Odour Threshold : No data available

pH : 4.1 - 4.6

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1.0044 g/cm³ (20 °C)

Solubility(ies)

Water solubility : slightly soluble

Partition coefficient: n- : No data available

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Acute oral toxicity : LD50 (Rat): 1,320 mg/kg

LD50 (Mouse): > 435 mg/kg

LD50 (Monkey): 1,500 mg/kg

Skin corrosion/irritation

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

Components:

Moxifloxacin HCL:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Moxifloxacin HCL:

Species : Rabbit

Result : Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: in vitro micronucleus test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay)
Application Route: Oral

Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

Components:

Moxifloxacin HCL:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 500 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Monkey

Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: negative

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: LOAEL: 20 mg/kg body weight

Symptoms: Skeletal malformations

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Moxifloxacin HCL:

Target Organs : Live

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Moxifloxacin HCL:

Species : Rat
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Species : Rat

NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

Target Organs : Liver

Symptoms : Liver disorders

Species : Rat

NOAEL : 20 mg/kg

Application Route : Oral

Exposure time : 6 Months

Target Organs : Liver

Symptoms : Liver disorders

Species : Monkey
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Symptoms : No adverse effects

Species : Monkey
NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Target Organs : Gastrointestinal tract

Symptoms : Vomiting

Species : Monkey
Application Route : Oral
Exposure time : 26 Weeks
Target Organs : Liver

Symptoms : Liver disorders

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Moxifloxacin HCL:

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness,

central nervous system effects, joint pain

12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen: Not applicable

ger aircraft)

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable

Marine pollutant : no

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

National Regulations

GB 6944/12268

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Marine pollutant : no

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the cata-

logue of hazardous chemicals and it does not meet the definition of hazardous chemicals and its principles

of determination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB : Not listed

18218)

Hazardous Chemicals for Priority Management under : Not listed

SAWS

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import : Not listed

and Export

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

The components of this product are reported in the following inventories:

AICS : not determined

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2024/09/28

Further information

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration: ICAO - International Civil Aviation Organization: IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-

according to GB/T 16483 and GB/T 17519



Moxifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2.0 2024/09/28 1731695-00015 Date of first issue: 2017/06/05

mendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN